Published by Iain Gilbert on 4th September 2024
(Sharecast News) - Drugmaker Indivior said on Wednesday that the primary and secondary endpoints of Aelis Farma's clinical Phase 2B study of AEF0117 use in participants with cannabis use disorder had not been met.
URL: http://www.digitallook.com/dl/news/story/34530819/...